Regeneron Pharmaceuticals Rating Reiterated by TheStreet (REGN)
Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “hold” rating reiterated by stock analysts at TheStreet in a report issued on Tuesday, Analyst Ratings.Net reports.
The analysts wrote, “Regeneron Pharmaceuticals (REGN) has been reiterated by TheStreet Ratings as a hold with a ratings score of C+. The company’s strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company’s earnings per share.”
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 2.58% on Tuesday, hitting $338.65. 233,930 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a 52 week low of $159.09 and a 52 week high of $348.25. The stock’s 50-day moving average is $296.5 and its 200-day moving average is $284.0. The company has a market cap of $33.576 billion and a P/E ratio of 91.24.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 11th. The company reported $2.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.97 by $1.27. The company had revenue of $610.00 million for the quarter, compared to the consensus estimate of $579.17 million. During the same quarter in the previous year, the company posted $1.47 earnings per share. The company’s revenue for the quarter was up 47.0% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $4.55 EPS for the current fiscal year.
REGN has been the subject of a number of other recent research reports. Analysts at McLean Capital Management upgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note on Friday. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Regeneron Pharmaceuticals in a research note on Friday. They now have a $344.00 price target on the stock. Finally, analysts at Oppenheimer downgraded shares of Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 13th. They now have a $325.00 price target on the stock, up previously from $310.00. They noted that the move was a valuation call. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Regeneron Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $317.91.
In other Regeneron Pharmaceuticals news, Director Alfred G. Gilman unloaded 5,000 shares of the company’s stock on the open market in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $340.00, for a total transaction of $1,700,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.